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expertise, patient indication, institution guidelines and cultivated practice. Regional 
authorities reimburse chemotherapeutics according to different tariffs and codes. 
METHODS: A systematic literature review of the bibliographic databases Medline 
and Embase was performed. In addition, hand searching of reimbursement databases, 
national reimbursement tariffs and semi-structured interviews with expert oncologists 
were completed. Data extraction and evidence synthesis from these sources formed 
the basis for this evaluation. RESULTS: Fifty-nine publications (16 manuscripts, 29 
study protocols, 14 EMEA Public Assessment Reports) and nine expert interviews 
across four countries were included. The eight mNSCLC drugs and their seven com-
binations result in a wide set of administration patterns with variation in treatment 
schedules, number of interventions per patient, and difference in treatment settings in 
terms of inpatient versus outpatient approaches. Calculation of the 6 monthly admin-
istration cost of seven drug regimes for mNSCLC in France, Germany and Spain 
results in a range of a2,970 to a19,792, most affected by inpatient or outpatient 
administration setting. CONCLUSIONS: The following factors were found to result 
in variations in administration costs: setting (i.e. inpatient/outpatient); frequency of 
administration (e.g. weekly); duration of single administration (10–120 minutes); 
length of cycle (total number of administrations) type of cycle length (ﬁxed or ﬂexible); 
health care professional administering (e.g. nurse or physician); concomitant drugs 
(e.g. saline) and drug dosage. Together with differences in country-speciﬁc reimburse-
ment tariffs, these factors create signiﬁcant variation in administration patterns and 
costs associated with the delivery of drugs for mNSCLC.
CANCER – Patient-Reported Outcomes Studies
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OBJECTIVES: To assess the overall health-related quality of life (HRQL) of children 
diagnosed with ALL across major phases of therapy and identify areas for remediation. 
METHODS: All children registered in the trial at participating centres (n  5) and 5 
years of age at assessment were eligible. HRQL assessments were collected from 
parents using Health Utilities Index Mark 3 (HUI3) during 4 standard phases of 
therapy: induction (4 weeks); CNS prophylaxis (3); intensiﬁcation (30); continuation 
(71). Differences in mean HRQL utilities were tested using ANOVA for demographic 
(age and gender) and clinical factors: risk status; phase; and randomization group. 
Statistical signiﬁcance was p  0.05 with multiple-testing adjustments. Quality-
adjusted life years (QALYs) were calculated by phases for patients and general popula-
tion controls. Frequency distributions identiﬁed attributes affected. RESULTS: 600 
assessments were collected. Overall completion rate was 77%. Mean utilities differed 
(p  0.001) among phases: 0.67 induction; 0.75 CNS; 0.79 intensiﬁcation; 0.87 con-
tinuation. There were no differences in mean utilities for demographic or clinical 
factors. QALY estimates were, for patients and controls: 0.05 and 0.07 induction; 
0.04 and 0.05 CNS; 0.46 and 0.54 intensiﬁcation; 1.19 and 1.27 continuation. Most 
of the total QALY difference was from intensiﬁcation (42%) and continuation (42%). 
Pain was the HUI3 attribute most frequently affected among patients: 52% during 
intensiﬁcation and 37% during continuation. Combinations of HUI3 disabilities were 
common. During intensiﬁcation, 65% of patients with moderate/severe emotional 
disability also had moderate/severe pain. During continuation, 67% of patients with 
moderate/severe ambulation disability also had moderate/severe pain. CONCLU-
SIONS: The vast majority of QALYs lost by patients was associated with two phases 
of treatment and one health attribute. Future research to improve HRQL during 
treatment for ALL should focus on reducing pain during intensiﬁcation and continua-
tion phases.
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OBJECTIVES: There is a growing literature of health state utility values in oncology, 
providing researchers with an increasing opportunity to draw on existing published 
values rather than obtaining new data. A review of utility studies would identify 
existing values and gaps in the current literature. Our objective was to conduct a rapid, 
comprehensive literature review capturing oncology speciﬁc utilities and disutilities for 
adverse events, associated with therapeutic area of oncology, in order to develop a 
utilities library. METHODS: A comprehensive search string and pre-determined eli-
gibility criteria guided a search of Embase.com and the Cochrane Library focusing on 
primary papers and recent robust systematic reviews published from 1999–2009. To 
guide data extraction and construct the utility library, categories were created and 
included cancer type; treatment information; methods of utility capture; and utility/
disutility value/range. RESULTS: We identiﬁed 362 studies estimating utility and disu-
tility values in oncology, in a wide range of cancer types. Breast and prostate cancers 
were the most commonly investigated (n  91 and n  49 respectively). Comparably, 
a paucity of utility values were reported for other cancers. Methods of utility elicitation 
varied in robustness and wide-ranging values were reported. The most common 
method of utility capture was EQ5D followed by the HUI and the Time-Trade-Off or 
Standard Gamble techniques. Conversely, only 1 study employed the SF-6D. Although 
the most common causes of cancer-related deaths are lung and colorectal cancer, we 
found fewer studies eliciting utilities for these cancers relative to breast and prostate 
cancers (n  21 and n  27 respectively). CONCLUSIONS: This study demonstrates 
the value in reviewing literature estimating utilities and disutilities in oncology. It 
highlights areas in oncology where identiﬁed utility values may be combined to 
produce more robust values and examine sources of variation.
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OBJECTIVES: Given that treatments for chronic lymphocytic leukaemia (CLL) are 
palliative rather than curative, evaluating the patient-perceived impacts of therapy is 
critical. To date, no utility studies from the patient or general public perspective have 
been conducted in CLL. Thus, the objective of this study was to measure preferences 
for health states associated with CLL treatment. METHODS: This was a cross-sec-
tional study of 89 members of the general population in the UK (England and Scot-
land). Using standard gamble, each participant valued four health states describing 
response status, six describing treatment-related toxicities based on Common Toxicity 
Criteria, and two describing line of treatment. The health states incorporated stan-
dardized descriptions of treatment response (symptoms have “improved,” “stabi-
lized,” or “gotten worse”), swollen glands, impact on daily activities, fatigue, appetite, 
and night sweats. Utility estimates ranged from 0.0, reﬂecting dead, to 1.0, reﬂecting 
full health. RESULTS: Complete response (CR) was the most preferred health state 
(mean utility, 0.91), followed by partial response (PR), 0.84; no change (NC), 0.78; 
and progressive disease (PD), 0.68. Among the toxicity states, grade I/II nausea and 
nausea/vomiting had the smallest utility decrements (both were 0.05), and grade III/
IV pneumonia had the greatest decrement (-0.20). The utility decrements obtained for 
toxicity states can be subtracted from utilities for CR, PR, NC, and PD, as appropriate. 
The utilities for second- and third-line treatments, which are attempted when symp-
toms worsen, were 0.71 and 0.65, respectively. In general, the sample was well-
matched according to the age and sex distribution for the adult UK population. No 
signiﬁcant differences in utilities were observed by age, sex, or knowledge/experience 
with leukaemia. CONCLUSIONS: This study reports UK population utilities for a 
universal set of CLL health states that incorporate intended treatment response and 
unintended toxicities. These utilities can be applied in future cost-effectiveness analyses 
of CLL treatment.
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OBJECTIVES: Cancer patients’ preferences and assessment of the risks and beneﬁts 
associated with cancer therapy may inﬂuence their decisions to continue their treat-
ment and eventually determine their satisfaction with the outcomes of treatment. The 
main objective of this study was to validate a Korean translation of the Cancer 
Therapy Satisfaction Questionnaire (CTSQ) for use in Korea to assess expectation 
and satisfaction with the treatments of traditional Korean medicine and integrative 
cancer therapy, combined western and traditional Korean medicine (TKM) received. 
METHODS: To evaluate the conceptual equivalence and consistency of the items and 
scales, forward translation, reconciliations, backward translation, and focus group 
discussions were performed. After completing translation procedures, a pilot test was 
conducted for cognitive testing. The Korean translation of CTSQ was completed by 
14 cancer patients treated by Korean traditional medicine and 10 patients by integra-
tive cancer therapy. RESULTS: Of 14 patients with TKM only and 10 patients with 
integrative therapy, gender distributions were similar. The mean (/sd) age were 
53.2(/13.7) and 55.2(/10.7) years for the TKM only and Integrative therapy 
group, respectively. Most patients were stage 4 (88.9%). Cronbach’s alphas for the 
internal consistency reliability of three domains, Expectations of Therapy (ET), Feel-
ings about Side Effects (FSE), Satisfaction with Therapy (SWT) were 0.78, 0.68, and 
0.77, respectively. In the TKM group, mean scores of ET, FSE, and SWT domains 
were 81.8/16.6, 80.8/22.9, and 82.1/14.3, respectively, whereas in the integra-
tive therapy group, mean scores were 86.0/11.5, 76.9/21.3, and 77.0/12.3, 
respectively. CONCLUSIONS: These results support the applications of the Korean 
CTSQ for the ﬁeld test in full scale assessing treatment satisfaction associated with 
both integrative cancer therapy and a single traditional Korean medicine.
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OBJECTIVES: Translation of patient reported outcomes (PRO) measures is an essen-
tial component of research methodology in preparation for multinational clinical 
